22nd Century Group, Inc. (NYSE American: XXII), a leading
plant-based, life science company driven by next generation
biotechnology, announced today that Mitchell R. Zeller, director of
the Center for Tobacco Products (CTP) at the U.S. Food and Drug
Administration (FDA), will provide an update on the FDA’s
Comprehensive Plan for Tobacco and Nicotine Products at the Food
and Drug Law Institute’s (FDLI) Tobacco and Nicotine Products
Regulation and Policy Conference on Wednesday October 21, 2020 at
11:15 a.m. ET.
In addition to Zeller’s presentation, 22nd
Century’s Vice President of Regulatory Science, John Pritchard,
will participate in the conference’s “Nicotine and Harm Reduction”
panel on Thursday, October 22, 2020 at 1:15 p.m. ET. 22nd Century’s
Michael Zercher, president and chief operating officer, and Steven
Przybyla, general counsel and corporate secretary, will also be in
attendance.
“I am delighted to participate in this important
conference and to support, with our reduced nicotine technology,
FDA’s plan to implement a reduced nicotine product standard,” said
Pritchard. “The science is clear. By limiting the nicotine content
of all combustible cigarettes to levels achieved in our VLN®
cigarettes, the FDA projects that five million adult smokers would
quit one year after implementation and over eight million American
lives would be saved by the end of the century. Our goal for this
conference, as in general, is to advance common-sense tobacco and
nicotine regulation and unite against the tragic toll of cigarette
addiction to improve public health in America.”
This year’s conference brings together a diverse
group of stakeholders, including public health advocates,
researchers, manufacturers, lawyers, consumer interest groups,
entrepreneurs, governmental agencies, and others to discuss
effective regulation across the broad spectrum of tobacco and
nicotine products in the United States.
Nicotine remains a central part of the FDA’s
landmark 2017 Comprehensive Plan for Tobacco and Nicotine
Regulation, which addresses the root cause of nearly half a million
American deaths each year, caused by highly addictive tobacco
products. Upon announcing the FDA’s plan to substantially reduce
the nicotine in cigarettes, former FDA Commissioner, Dr. Scott
Gottlieb remarked: “The overwhelming amount of death and disease
attributable to tobacco is caused by addiction to cigarettes – the
only legal consumer product that, when used as intended, will kill
half of all long-term users.”
Panelists will examine the public health impact
of regulating nicotine content across the broad spectrum of tobacco
and nicotine products; the ways in which policies can help minimize
users' health risks; and the mitigation of potential unintended
consequences. Pritchard will also discuss 22nd Century’s role in
ensuring the adoption of the FDA’s proposed reduced nicotine
product standard, requiring all cigarettes sold in the U.S. to be
“minimally... or non-addictive.” 22nd Century is committed to
making reduced nicotine technology available to the entire tobacco
industry. Licensing the Company’s reduced nicotine technology to
tobacco companies will allow the industry to deliver on their
commitments to reduce combustible cigarette consumption and to
comply with the FDA’s reduced nicotine standard.
22nd Century believes that the FDA is in the
final stages of its decision-making process for the Company’s
Modified Risk Tobacco Product (MRTP) Applications for VLN®. An
authorization decision by the FDA will bring to market the first
and only combustible cigarettes available with 95% less nicotine
compared to other cigarettes, further demonstrating the technical
feasibility of the FDA’s generationally significant product
standard.
Pritchard’s presentation will be accessible in
the Investors section of 22nd Century’s website, under Events.
About 22nd Century Group,
Inc.22nd Century Group, Inc. (NYSE American: XXII) is a
leading, plant-based, life science company that develops and
provides disruptive, commercial solutions to the life science,
consumer products, and pharmaceutical markets. Working with tobacco
and hemp/cannabis plants, 22nd Century is dedicated to its mission
of reducing the harm caused by smoking. The Company’s proprietary
reduced nicotine VLN® cigarettes contain 95% less nicotine than
conventional brands and are poised to disrupt the more than $800
billion global tobacco market. 22nd Century owns or controls
more than 200 issued and pending patents related to the tobacco and
hemp/cannabis plants.
Learn more at xxiicentury.com, on
Twitter @_xxiicentury and on LinkedIn.
Cautionary Note Regarding
Forward-Looking StatementsExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements.
Forward-looking statements typically contain terms such as
“anticipate,” “believe,” “consider,” “continue,” “could,”
“estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,”
“intend,” “likely,” “may,” “plan,” “potential,” “predict,”
“preliminary,” “probable,” “project,” “promising,” “seek,”
“should,” “will,” “would,” and similar expressions. Actual results
might differ materially from those explicit or implicit in
forward-looking statements. Important factors that could cause
actual results to differ materially are set forth in “Risk Factors”
in our Annual Report on Form 10-K filed on March 11, 2020 and in
our subsequently filed Quarterly Report on Form 10-Q. We undertake
no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events, or
otherwise, except as otherwise required by law.
All information provided in this release is as of the date
hereof, and we assume no obligation to and do not intend to update
these forward-looking statements, except as required by law.
Investor Relations & Media Contact:Mei
KuoDirector, Communications & Investor Relations22nd Century
Group, Inc.(716) 300-1221mkuo@xxiicentury.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From May 2023 to May 2024